Oxycontin is a drug owned by Purdue Pharma Lp. It is protected by 32 US drug patents filed from 2013 to 2024. Out of these, 22 drug patents are active and 10 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 29, 2030. Details of Oxycontin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9522919 | Oxycodone compositions |
Mar, 2025
(5 months from now) | Active |
| US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(5 months from now) | Active |
| US10407434 | Process for preparing oxycodone compositions |
Mar, 2025
(5 months from now) | Active |
| US10696684 | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(5 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8894987 | Tamper resistant dosage forms |
Mar, 2030
(5 years from now) | Active |
| US9775808 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US9492392 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US8808741 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US9763933 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US11304909 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US11964056 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US9492391 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US8894988 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US9492393 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US11304908 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US9770416 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US9492389 | Tamper resistant dosage forms |
Aug, 2027
(2 years from now) | Active |
| US7776314 | Abuse-proofed dosage system |
Apr, 2025
(5 months from now) | Active |
| US12060361 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(5 months from now) | Active |
| US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(5 months from now) | Active |
| US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(5 months from now) | Active |
| US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(5 months from now) | Active |
| US8114383 | Abuse-proofed dosage form |
Oct, 2024
(14 days ago) |
Expired
|
| US8309060 | Abuse-proofed dosage form |
Nov, 2023
(11 months ago) |
Expired
|
| US10130591 | Abuse-proofed dosage form |
Nov, 2023
(11 months ago) |
Expired
|
| US10675278 | Crush resistant delayed-release dosage forms |
Nov, 2023
(11 months ago) |
Expired
|
| US9675610 | Abuse-proofed dosage form |
Jun, 2023
(1 year, 4 months ago) |
Expired
|
| US10369109 | Abuse-proofed dosage form |
Jun, 2023
(1 year, 4 months ago) |
Expired
|
| US8337888 | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(2 years ago) |
Expired
|
| US9060976 | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(2 years ago) |
Expired
|
| US6488963 | Hot-melt extrudable pharmaceutical formulation |
Jun, 2017
(7 years ago) |
Expired
|
| US5508042 | Controlled release oxycodone compositions |
Apr, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oxycontin's patents.
Latest Legal Activities on Oxycontin's Patents
Given below is the list of recent legal activities going on the following patents of Oxycontin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 15 Jul, 2024 | US10675278 |
| Maintenance Fee Reminder Mailed Critical | 01 Jul, 2024 | US8309060 |
| Electronic Review Critical | 07 Jun, 2024 | US11964056 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9522919 (Litigated) |
| Email Notification Critical | 23 Apr, 2024 | US11964056 |
| Mail Patent eGrant Notification | 23 Apr, 2024 | US11964056 |
| Patent eGrant Notification | 23 Apr, 2024 | US11964056 |
| Recordation of Patent eGrant | 23 Apr, 2024 | US11964056 |
| Patent Issue Date Used in PTA Calculation Critical | 23 Apr, 2024 | US11964056 |
| Recordation of Patent Grant Mailed Critical | 23 Apr, 2024 | US11964056 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Oxycontin and ongoing litigations to help you estimate the early arrival of Oxycontin generic.
Oxycontin's Litigations
Oxycontin been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 11, 2016, against patent number US9060976. The petitioner Amneal Pharmaceuticals, LLC, challenged the validity of this patent, with PURDUE PHARMA L.P. as the respondent. Click below to track the latest information on how companies are challenging Oxycontin's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9492392 | February, 2018 |
Terminated-Settled
(21 Aug, 2018) | Purdue Pharma L.P. | Kashiv Pharma, LLC |
| US9492393 | February, 2018 |
Terminated-Settled
(21 Aug, 2018) | Purdue Pharma L.P. | Kashiv Pharma, LLC |
| US9060976 | May, 2016 |
FWD Entered
(08 Nov, 2017) | PURDUE PHARMA L.P. | Amneal Pharmaceuticals, LLC |
FDA has granted some exclusivities to Oxycontin. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Oxycontin, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Oxycontin.
Exclusivity Information
Oxycontin holds 2 exclusivities. All of its exclusivities have expired in 2018. Details of Oxycontin's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Several oppositions have been filed on Oxycontin's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Oxycontin's generic, the next section provides detailed information on ongoing and past EP oppositions related to Oxycontin patents.
Oxycontin's Oppositions Filed in EPO
Oxycontin has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 14, 2007, by Purdue Pharma Lp. This opposition was filed on patent number EP04763834A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP06706682A | Dec, 2017 | G. L. Pharma GmbH | Revoked |
| EP11186168A | Oct, 2016 | James Poole Limited | Opposition rejected |
| EP10011792A | Oct, 2015 | Hoffmann Eitle | Granted and Under Opposition |
| EP10011792A | Oct, 2015 | Setna, Rohan P. | Granted and Under Opposition |
| EP10011792A | Oct, 2015 | James Poole Limited | Granted and Under Opposition |
| EP10011792A | Oct, 2015 | Acino Pharma AG | Granted and Under Opposition |
| EP05730345A | Dec, 2011 | Actavis group PTC ehf | Patent maintained as amended |
| EP05730345A | Dec, 2011 | Acino Pharma AG | Patent maintained as amended |
| EP05730345A | Dec, 2011 | Elend, Almut Susanne | Patent maintained as amended |
| EP2005006983W | Oct, 2009 | Sanofi-Aventis Deutschland GmbH | Patent maintained as amended |
| EP2005006983W | Oct, 2009 | Ypsomed AG | Patent maintained as amended |
| EP04763833A | Mar, 2008 | Purdue Pharma LP | Opposition rejected |
| EP04763834A | Dec, 2007 | Purdue Pharma LP | Opposition rejected |
US patents provide insights into the exclusivity only within the United States, but Oxycontin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Oxycontin's family patents as well as insights into ongoing legal events on those patents.
Oxycontin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Oxycontin's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 29, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Oxycontin Generic API suppliers:
Oxycodone Hydrochloride is the generic name for the brand Oxycontin. 26 different companies have already filed for the generic of Oxycontin, with Epic Pharma Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Oxycontin's generic
Alternative Brands for Oxycontin
Oxycontin which is used for managing moderate to severe pain that requires long-term opioid treatment when other options are inadequate., has several other brand drugs in the same treatment category and using the same active ingredient (Oxycodone Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Bdsi |
| |||||||
| Collegium Pharm Inc |
| |||||||
| Purdue Pharma Lp |
| |||||||
| Zyla |
| |||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Oxycodone Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Mallinckrodt Inc |
| |
| Pfizer |
| |
| Protega Pharms |
| |
| Zyla |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Oxycodone Hydrochloride, Oxycontin's active ingredient. Check the complete list of approved generic manufacturers for Oxycontin
About Oxycontin
Oxycontin is a drug owned by Purdue Pharma Lp. It is used for managing moderate to severe pain that requires long-term opioid treatment when other options are inadequate. Oxycontin uses Oxycodone Hydrochloride as an active ingredient. Oxycontin was launched by Purdue Pharma Lp in 2010.
Approval Date:
Oxycontin was approved by FDA for market use on 05 April, 2010.
Active Ingredient:
Oxycontin uses Oxycodone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Oxycodone Hydrochloride ingredient
Treatment:
Oxycontin is used for managing moderate to severe pain that requires long-term opioid treatment when other options are inadequate.
Dosage:
Oxycontin is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 20MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 10MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 15MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 40MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 80MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 60MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 160MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |